In the present study, the prophylactic oral administration and oral therapeutic of TFA prevented the progression of colonic fibrosis in TNBS-induced chronic colitis via suppression of TGF-β and, IGF and α-SMA expression to reduce mesenchymal cell production. This evidence concerns the gene ACTA1 and Chronic colitis.